Aspectos actuales del síndrome de Sjögrenetiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento
- Carolina Diez Morrondo
- José Manuel Lema Gontad
- Noelia Álvarez Rivas
- Antonio Atanes Sandoval
- Javier de Toro Santos
- José Antonio Pinto Tasende
- Fausto Galdo Fernández
ISSN: 1577-3566
Year of publication: 2010
Volume: 11
Issue: 2
Pages: 70-76
Type: Article
More publications in: Seminarios de la Fundación Española de Reumatología
Sustainable development goals
Abstract
Sjögren's Syndrome (SS) is a chronic autoimmune disorder of the exbaocrine glands with associated lymphocytic infiltrates of the affected glands. SS occurs in a primary form not associated with other diseases and in a secondary form that complicates other rheumatic conditions. In both primary and secondary SS, decreased exocrine gland function leads to the �sicca complex�, a combination of dry eyes (xerophthalmia) and dry mouth (xerostomia). The clinical manifestations also include extraglandular disease features (skin, joints and muscles, lungs, kidneys, gastrointestinal tract). A variety of classification schemes have been proposed and discussed in the literature since the 1980s. The latest criteria, known as the American-European classification criteria for SS, were proposed in 2002. These criteria suggest that diagnosis of primary SS requires 4 of 6 criteria, including a positive minor-salivary biopsy sample and/or SS-A/SS-B antibodies. Therapy can be grouped into two separate aspects: treatment of dry eyes and dry mouth (replacement tears, muscarinic agonist agents�) and treatment of extraglandular manifestations (steroidal and non-steroidal anti-inflammatory agents, disease modifying agents, cytotoxic agents and biological therapies).